Offices:
Oslo
Investors:
we tracked 3 investors
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Total investments received (USD) - we tracked 4 transactions
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Vaccibody AS is a privately held vaccine company based on the technology conceived at the University of Oslo and Oslo University Hospital in the laboratories of Professors Bjarne Bogen and Inger Sandlie.
Vaccibody AS has developed a unique and innovative vaccine platform with the aim to treat and prevent pre-cancerous diseases or cancer as well as infectious diseases. Through its innovative design Vaccibody’s proprietary vaccine platform generates rapid, durable and broad antibody and T cell responses leading to remarkably potent vaccines.
Vaccibody has developed compelling preclinical data and initiated the first clinical trial with VB10.16, a therapeutic vaccine against cervical precancerous lesion. Also, Vaccibody has initiated development of neoantigen-based individualized cancer vaccines and is using the Vaccibody technology to generate first-in-class therapeutics to treat cancers with a high unmet medical need.
Companies with similar profile to Vaccibody:
| Company | Criteria |
|---|
 Avexxin46% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
- At least one vc investor: Sarsia Seed Management
|
 Asarina Pharma44% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| BerGenBio 34% | - Similar business models: B2B
- At least one vc investor: Sarsia Seed Management
- Total raised in a similar range: 10M+ USD
|
| Vironova 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| Ilya Pharma 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| Athera 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
 3Z Pharmaceuticals34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| Trialbee 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
 TILT Biotherapeutics33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| Airsonett 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| Blueprint Genetics 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| BoneSupport 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| InDex Pharmaceuticals 33% | - Similar verticals: Pharma
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| Listen AS 33% | - Similar verticals: Health services
- Similar business models: B2B
- At least one other investor: Inven2
|
| BC Platforms 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| AMRA 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| OncoImmunity 33% | - Similar verticals: Health services
- Similar business models: B2B
- At least one other investor: RadForsk
|
 Acarix33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| Conceptomed 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| OxThera 33% | - Similar verticals: Pharma
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
